The U.S. Senate Committee on Health, Education, Labor and Pensions has initiated an investigation into the pricing of Novo Nordisk's diabetes and weight loss drugs, Ozempic and Wegovy, in the United States. Senator Bernie Sanders, the committee chair, has penned a letter to Novo's CEO, requesting further details on the pricing strategy for these medications, particularly in comparison to prices in other countries.
One of the primary concerns raised by the committee is the significantly higher prices of Ozempic and Wegovy in the U.S. compared to other nations. The investigation aims to shed light on the reasons behind these price disparities and assess whether Novo Nordisk plans to make substantial reductions to both the list price and the net price of these drugs in the American market.
Furthermore, the committee is seeking clarification on the pricing discrepancy between Wegovy and Ozempic, given that both drugs contain the same active compound. Of particular interest is the rationale behind charging a higher price for Wegovy, the weight loss drug, compared to Ozempic, which is approved for diabetes treatment.
In response to the Senate committee's inquiry, Novo Nordisk has reiterated its commitment to collaborating with policymakers to enhance patient access and affordability of medications. The company has expressed willingness to engage in dialogue and work towards solutions that ensure all patients can benefit from these innovative treatments.
Ozempic and Wegovy, both belonging to the class of GLP-1 agonists, have been proven to be effective in reducing food cravings and slowing down stomach emptying in patients. As the investigation unfolds, stakeholders are eagerly awaiting further information regarding Novo Nordisk's pricing strategies and its plans for addressing concerns raised by the Senate committee.